DE69819488D1 - Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes - Google Patents

Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes

Info

Publication number: DE69819488D1
Authority: DE; Germany
Prior art keywords: glp; upper gastrointestinal; gastrointestinal tract; methods; tissue
Prior art date: 1997-05-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69819488T

Other languages

English (en)

Other versions

DE69819488T2 (de

Inventor

J Drucker

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

1149336 Ontario Inc

Original Assignee

1149336 Ontario Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-05-16

Filing date

1998-05-15

Publication date

2003-12-11

1997-07-23 Priority claimed from GBGB9715481.9A external-priority patent/GB9715481D0/en

1998-04-13 Priority claimed from US09/059,504 external-priority patent/US6051557A/en

1998-05-15 Application filed by 1149336 Ontario Inc filed Critical 1149336 Ontario Inc

2003-12-11 Application granted granted Critical

2003-12-11 Publication of DE69819488D1 publication Critical patent/DE69819488D1/de

2004-08-26 Publication of DE69819488T2 publication Critical patent/DE69819488T2/de

2018-05-16 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

102400000326 Glucagon-like peptide 2 Human genes 0.000 title abstract 6
101800000221 Glucagon-like peptide 2 Proteins 0.000 title abstract 6
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 title abstract 6
210000002438 upper gastrointestinal tract Anatomy 0.000 title abstract 5
239000000556 agonist Substances 0.000 title abstract 2
230000000694 effects Effects 0.000 title 1
239000000813 peptide hormone Substances 0.000 abstract 3
230000002496 gastric effect Effects 0.000 abstract 2
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
102400000321 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
210000003238 esophagus Anatomy 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
230000004968 inflammatory condition Effects 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
230000035755 proliferation Effects 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1
210000002784 stomach Anatomy 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)

DE69819488T 1997-05-16 1998-05-15 Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes Expired - Lifetime DE69819488T2 (de)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US59504		1987-06-08
US4675497P	1997-05-16	1997-05-16
US46754P		1997-05-16
GBGB9715481.9A GB9715481D0 (en)	1997-07-23	1997-07-23	Methods of enhancing functioning of the upper gastrointestinal tract
GB9715481		1997-07-23
US09/059,504 US6051557A (en)	1997-05-16	1998-04-13	Methods of enhancing functioning of the upper gastrointestinal tract
PCT/CA1998/000497 WO1998052600A1 (en)	1997-05-16	1998-05-15	Methods of enhancing functioning of the upper gastrointestinal tract

Publications (2)

Publication Number	Publication Date
DE69819488D1 true DE69819488D1 (de)	2003-12-11
DE69819488T2 DE69819488T2 (de)	2004-08-26

Family

ID=27268946

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69819488T Expired - Lifetime DE69819488T2 (de)	1997-05-16	1998-05-15	Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes

Country Status (13)

Country	Link
EP (1)	EP0981362B1 (de)
JP (2)	JP4699576B2 (de)
CN (1)	CN1264307B (de)
AT (1)	ATE253375T1 (de)
AU (1)	AU746633B2 (de)
BR (1)	BR9808804A (de)
CA (1)	CA2289652C (de)
DE (1)	DE69819488T2 (de)
DK (1)	DK0981362T3 (de)
ES (1)	ES2210756T3 (de)
MX (1)	MXPA99010523A (de)
PT (1)	PT981362E (de)
WO (1)	WO1998052600A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69819488T2 (de) *	1997-05-16	2004-08-26	1149336 Ontario Inc., Toronto	Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
GB9905416D0 (en) *	1999-03-09	1999-05-05	Allelix Biopharma	Small molecules having GLP-2 like activity
RU2164349C1 (ru) *	1999-07-27	2001-03-20	Нижегородская государственная медицинская академия	Способ определения стоматологического статуса
AU2020501A (en) *	1999-12-08	2001-06-18	1149336 Ontario Inc.	Chemotherapy treatment
PT1326630E (pt) *	2000-09-18	2008-09-02	Sanos Bioscience As	Utilização de péptidos glp-2
US7371721B2 (en)	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en)	2000-09-18	2007-03-06	Sanos Bioscience A/S	Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US7411039B2 (en)	2002-10-14	2008-08-12	Novo Nordisk A/S	GLP-2 compounds, formulations, and uses thereof
DK1809318T3 (da)	2004-11-01	2013-09-08	Nps Pharma Inc	Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
ES2361095T5 (es)	2005-05-04	2021-11-23	Zealand Pharma As	Análogos del péptido 2 tipo glucagón (GLP-2)
NZ576260A (en) *	2006-11-08	2012-04-27	Zealand Pharma As	GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2
US20110171164A1 (en) *	2008-09-19	2011-07-14	Nektar Therapeutics	Polymer conjugates of glp-2-like peptides
JP5908478B2 (ja) *	2010-08-30	2016-04-26	エヌピーエスファーマシューティカルズインコーポレイテッドＮｐｓＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	ｈ「Ｇｌｙ２」ＧＬＰ−２の固相合成
EP2844670B1 (de)	2012-05-03	2017-12-06	Zealand Pharma A/S	Glucagon-artige peptid-2-analoga (glp-2-)analoga
US20180200301A1 (en) *	2015-05-21	2018-07-19	Shanghai Institutes For Biological Sciences Chinese Academy Of Sciences	Low-Oxygen-Treated Mesenchymal Stem Cell and Use Thereof
DK3551651T3 (da)	2016-12-09	2024-05-13	Zealand Pharma As	Acylerede glp-1/glp-2-dobbeltagonister
PE20200678A1 (es)	2017-06-16	2020-06-11	Zealand Pharma As	Posologias para la administracion de analogos de peptido de tipo glucagon-2 (glp-2)
CN108273038B (zh) *	2018-03-16	2019-03-19	中国人民解放军军事科学院军事医学研究院	防治肠型放射病的药物组合物
CN110226566A (zh) *	2019-07-12	2019-09-13	南京中医药大学	一种放射性口腔黏膜炎动物模型的造模方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK27885A (da) *	1985-01-22	1986-07-23	Novo Industri As	Fremstilling af peptider
US5990077A (en) *	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
CA2251576C (en) *	1996-04-12	2012-08-21	1149336 Ontario Inc.	Glucagon-like peptide-2 analogs
AU5696298A (en) *	1996-12-06	1998-06-29	Amgen, Inc.	Keratinocyte growth factors and uses thereof
US5952301A (en) *	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
DE69819488T2 (de) *	1997-05-16	2004-08-26	1149336 Ontario Inc., Toronto	Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes

1998
- 1998-05-15 DE DE69819488T patent/DE69819488T2/de not_active Expired - Lifetime
- 1998-05-15 AU AU75163/98A patent/AU746633B2/en not_active Ceased
- 1998-05-15 AT AT98922546T patent/ATE253375T1/de active
- 1998-05-15 WO PCT/CA1998/000497 patent/WO1998052600A1/en active IP Right Grant
- 1998-05-15 CN CN988073307A patent/CN1264307B/zh not_active Expired - Fee Related
- 1998-05-15 ES ES98922546T patent/ES2210756T3/es not_active Expired - Lifetime
- 1998-05-15 JP JP54974198A patent/JP4699576B2/ja not_active Expired - Fee Related
- 1998-05-15 CA CA2289652A patent/CA2289652C/en not_active Expired - Fee Related
- 1998-05-15 MX MXPA99010523A patent/MXPA99010523A/es active IP Right Grant
- 1998-05-15 EP EP98922546A patent/EP0981362B1/de not_active Expired - Lifetime
- 1998-05-15 DK DK98922546T patent/DK0981362T3/da active
- 1998-05-15 BR BR9808804-1A patent/BR9808804A/pt not_active Application Discontinuation
- 1998-05-15 PT PT98922546T patent/PT981362E/pt unknown
2009
- 2009-07-22 JP JP2009171401A patent/JP2009280598A/ja active Pending

Also Published As

Publication number	Publication date
CN1264307B (zh)	2013-10-30
ES2210756T3 (es)	2004-07-01
JP4699576B2 (ja)	2011-06-15
PT981362E (pt)	2004-03-31
DE69819488T2 (de)	2004-08-26
WO1998052600A9 (en)	2000-03-09
HK1030160A1 (en)	2001-04-27
EP0981362B1 (de)	2003-11-05
CN1264307A (zh)	2000-08-23
DK0981362T3 (da)	2004-03-15
AU7516398A (en)	1998-12-11
EP0981362A1 (de)	2000-03-01
CA2289652C (en)	2012-02-28
ATE253375T1 (de)	2003-11-15
JP2002502369A (ja)	2002-01-22
JP2009280598A (ja)	2009-12-03
BR9808804A (pt)	2001-09-18
MXPA99010523A (es)	2004-09-01
WO1998052600A1 (en)	1998-11-26
AU746633B2 (en)	2002-05-02
CA2289652A1 (en)	1998-11-26

Publication	Publication Date	Title
DE69819488D1 (de)	2003-12-11	Verwendung von glp-2 agonisten zur verbesserung der wirkung des oberen gastrointestinaltraktes
ATE233096T1 (de)	2003-03-15	Zusammensetzungen und methoden zur steigerung der darmfunktion
ATE450269T1 (de)	2009-12-15	Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
DE69736634D1 (de)	2006-10-19	Antagonisten des intestinotrophen glp-2 peptides
DE69521796D1 (de)	2001-08-23	Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndromes
ATE259829T1 (de)	2004-03-15	Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
ATE531382T1 (de)	2011-11-15	Behandlungsmethoden von entzündungskrankheiten mit spezifisch an menschliches angiopoietin-2 bindenden wirkstoffen
ATE322902T1 (de)	2006-04-15	Verwendung von azetogenischen hydrogenotrophischen stämmen zur vorbeugung und behandlung von verdauungskrankheiten
HUP0004560A2 (hu)	2001-04-28	Törést gyógyító PTHrP analógok
WO1998033509A3 (en)	1999-03-11	Useful properties of human lactoferrin and variants thereof
EA200400376A1 (ru)	2005-06-30	Пептиды, полученные из казеина, и их использование в терапии
EA200100872A1 (ru)	2002-02-28	Композиция валдекоксиба
BRPI0607097B8 (pt)	2021-05-25	uso de um peptídeo imunogênico para a fabricação de um medicamento para o tratamento, prevenção ou redução de infecção por papilomavírus
ATE475716T1 (de)	2010-08-15	Zusammenstellungen zur behandlung von neurodegenerativen erkrankungen
DK0810829T3 (da)	2000-08-28	Aminosyresammensætninger og anvendelse deraf til klinisk ernæring
MXPA05002991A (es)	2005-10-05	Analogos de ghrh.
ATE198050T1 (de)	2000-12-15	Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
JP2006506942A5 (de)	2006-04-13
ATE280777T1 (de)	2004-11-15	Bradykinin-antagonist peptide mit n- substituierten glycinen
ATE234111T1 (de)	2003-03-15	Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
DE60326723D1 (de)	2009-04-30	Verwendung von zusammensetzungen mit der biologischen aktivität der vasoaktiven intestinalen peptide zur behandlung von sarcoidose
NO20011537L (no)	2001-05-28	Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
ATE313561T1 (de)	2006-01-15	Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE69326122D1 (de)	1999-09-30	Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
ATE552271T1 (de)	2012-04-15	Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon

Legal Events

Date	Code	Title	Description
2004-12-02	8364	No opposition during term of opposition